Terms: = Ovarian cancer AND NF1, NFNS, 4763, ENSG00000196712, P21359 AND Diagnosis
17 results:
1. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
ElNaggar A; Robins D; Baca Y; Arguello D; Ulm M; Arend R; Mantia-Smaldone G; Chu C; Winer I; Holloway R; Krivak T; Jones N; Galvan-Turner V; Herzog TJ; Brown J
Gynecol Oncol; 2022 Nov; 167(2):306-313. PubMed ID: 36229265
[TBL] [Abstract] [Full Text] [Related]
3. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S
Br J Cancer; 2022 Nov; 127(8):1479-1486. PubMed ID: 35869143
[TBL] [Abstract] [Full Text] [Related]
4. Comparison of cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic cancer Center vs in the General Population From 1985 to 2020.
Landry JP; Schertz KL; Chiang YJ; Bhalla AD; Yi M; Keung EZ; Scally CP; Feig BW; Hunt KK; Roland CL; Guadagnolo A; Bishop AJ; Lazar AJ; Slopis JM; McCutcheon IE; Torres KE
JAMA Netw Open; 2021 Mar; 4(3):e210945. PubMed ID: 33734413
[TBL] [Abstract] [Full Text] [Related]
5. Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R; Castillejo MI; Dámaso E; Díez-Obrero V; Garrigos N; Molina T; Codoñer-Alejos A; Segura Á; Sánchez-Heras AB; Castillejo A; Soto JL
Cancer Commun (Lond); 2021 Mar; 41(3):218-228. PubMed ID: 33630411
[TBL] [Abstract] [Full Text] [Related]
6. Crowdsourcing to measure financial toxicity in gynecologic oncology.
Esselen KM; Stack-Dunnbier H; Gompers A; Hacker MR
Gynecol Oncol; 2021 May; 161(2):595-600. PubMed ID: 33551197
[TBL] [Abstract] [Full Text] [Related]
7. A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients.
Zhang Y; Shi X; Zhang J; Chen X; Zhang P; Liu A; Zhu T
Sci Rep; 2021 Jan; 11(1):387. PubMed ID: 33432021
[TBL] [Abstract] [Full Text] [Related]
8. Computational-based identification and analysis of globally expressed differential genes in high-grade serous ovarian carcinoma cell lines.
Masood F; Khan W; Uddin R
Comput Biol Chem; 2020 Oct; 88():107333. PubMed ID: 32738584
[TBL] [Abstract] [Full Text] [Related]
9. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
[TBL] [Abstract] [Full Text] [Related]
10. Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome.
Melendez-Zajgla J; Mercado-Celis GE; Gaytan-Cervantes J; Torres A; Gabiño NB; Zapata-Tarres M; Juarez-Villegas LE; Lezama P; Maldonado V; Ruiz-Monroy K; Mendoza-Caamal E
Sci Rep; 2018 Feb; 8(1):3252. PubMed ID: 29459759
[TBL] [Abstract] [Full Text] [Related]
11. Associations Between cancer Predisposition Testing Panel Genes and Breast cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract] [Full Text] [Related]
12. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract] [Full Text] [Related]
13. Exonic Splicing Mutations Are More Prevalent than Currently Estimated and Can Be Predicted by Using In Silico Tools.
Soukarieh O; Gaildrat P; Hamieh M; Drouet A; Baert-Desurmont S; Frébourg T; Tosi M; Martins A
PLoS Genet; 2016 Jan; 12(1):e1005756. PubMed ID: 26761715
[TBL] [Abstract] [Full Text] [Related]
14. Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Uehara Y; Oda K; Ikeda Y; Koso T; Tsuji S; Yamamoto S; Asada K; Sone K; Kurikawa R; Makii C; Hagiwara O; Tanikawa M; Maeda D; Hasegawa K; Nakagawa S; Wada-Hiraike O; Kawana K; Fukayama M; Fujiwara K; Yano T; Osuga Y; Fujii T; Aburatani H
PLoS One; 2015; 10(6):e0128066. PubMed ID: 26043110
[TBL] [Abstract] [Full Text] [Related]
15. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
Zhang J; Shi Y; Lalonde E; Li L; Cavallone L; Ferenczy A; Gotlieb WH; Foulkes WD; Majewski J
BMC Cancer; 2013 Mar; 13():146. PubMed ID: 23522120
[TBL] [Abstract] [Full Text] [Related]
16. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome.
Kratz CP; Holter S; Etzler J; Lauten M; Pollett A; Niemeyer CM; Gallinger S; Wimmer K
J Med Genet; 2009 Jun; 46(6):418-20. PubMed ID: 19293170
[TBL] [Abstract] [Full Text] [Related]
17. The use of ancestral haplotypes in the molecular diagnosis of familial breast cancer.
Frosk P; Burgess S; Dyck T; Jobse R; Spriggs EL
Genet Test; 2007; 11(3):208-15. PubMed ID: 17949280
[TBL] [Abstract] [Full Text] [Related]
